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Development of a Porous Poly(DL-lactic acid-co-glycolic acid)-Based
Scaffold for Mastoid Air-Cell Regeneration
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Objectives/Hypothesis: To develop a porous, biodegradable scaffold for mastoid air-cell regeneration.
Study Design: In vitro development of a temperature-sensitive poly(DL-lactic acid-co-glycolic acid)/poly(ethylene glycol)
(PLGA/PEG) scaffold tailored for this application.
Methods: Human mastoid bone microstructure and porosity were investigated using micro-computed tomography.
PLGA/PEG-alginate scaffolds were developed, and scaffold porosity was assessed. Human bone marrow mesenchymal stem
cells (hBM-MSCs) were cultured on the scaffolds in vitro. Scaffolds were loaded with ciprofloxacin, and release of ciprofloxa-
cin over time in vitro was assessed.
Results: Porosity of human mastoid bone was measured at 83% with an average pore size of 1.3 mm. PLGA/PEG-algi-
nate scaffold porosity ranged from 43% to 78% depending on the alginate bead content. The hBM-MSCs proliferate on the
scaffolds in vitro, and release of ciprofloxacin from the scaffolds was demonstrated over 7 to 10 weeks.
Conclusions: The PLGA/PEG-alginate scaffolds developed in this study demonstrate similar structural features to human mas-
toid bone, support cell growth, and display sustained antibiotic release. These scaffolds may be of potential clinical use in mastoid
air-cell regeneration. Further in vivo studies to assess the suitability of PLGA/PEG-alginate scaffolds for this application are required.
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INTRODUCTION
The mastoid portion of the temporal bone is com-
posed of interconnected air-filled chambers. This mastoid
air-cell system is reported to have a number of impor-
tant functions including sound conduction, maintaining
pressure regulation, gas exchange, material secretion,
waste excretion, and middle ear cavity aeration.1–3
Following mastoidectomy, mastoid obliteration proce-
dures are focused on filling the mastoid cavity and not
on repair of the mastoid bone structure. However, the
only way to restore the vital functions of the mastoid is
to fully regenerate the air cells within the bone.
Various polymers have been investigated for use as
scaffolds in bone regeneration, including poly(DL-lactic
acid-co-glycolic acid) (PLGA), which has a long history of
use as a degradable implant material.4 As previously
described by Dhillon et al., blending PLGA with a plasti-
cizer such as poly(ethylene glycol) (PEG) allows the pro-
duction of temperature-sensitive particles with a reduced
glass transition temperature (Tg) of 37
C.5 When these
particles are mixed with a carrier solution at room temper-
ature, a paste is formed that can be molded into any size or
shape. The paste then hardens into a solid scaffold at 37C
due to temperature-induced PEG leaching. The ability of
this scaffold system to regenerate bone in vivo has recently
been demonstrated in a mouse calvarial defect model.6
We describe the modification of this scaffold tech-
nology for potential use in mastoid air-cell regeneration.
A key advantage is the ability to paste the material into
a cavity of any size or shape followed by scaffold solidifi-
cation at body temperature. To optimize the scaffold
structure, we describe the inclusion of alginate beads in
the formulation to act as a porogen, creating scaffolds
with a high level of macroporosity. We also investigate
in vitro release of ciprofloxacin from the scaffolds with
the intention of providing local, sustained antibiotic
delivery to decrease postoperative infections or continua-
tion of underlying infections of the middle ear.
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MATERIALS AND METHODS
Mastoid Bone Sample Preparation
A section of mastoid bone approximately 3 3 3 cm was
excised from fresh-frozen human cadaveric temporal bone.
PLGA/PEG Particle Production
Particles were fabricated from blends of PLGA 85:15 DLG
4CA, 53 kDa (Lakeshore Biomaterials, Birmingham, AL) and
PEG 400 (Sigma-Aldrich, Poole, UK) as previously described by
Dhillon et al.5 Briefly, a mixture of 93.5%:6.5% PLGA:PEG (wt/
vol) was blended at 80C to 90C, mixed, and allowed to cool.
Cooled polymer was ground into particles and sieved to obtain
the 100- to 200-lm size fraction.
Alginate Bead Fabrication
A solution of 1% (wt/vol) sodium alginate (Acros Organics,
Loughborough, UK) was prepared in phosphate-buffered saline
(PBS). A total of 10 mL of alginate solution was loaded into a
syringe and ejected from a 23-gauge needle into a gently agitated
bath of 25 mL 5% (wt/vol) calcium chloride (Sigma-Aldrich). The
beads were strained using a 100 lm sieve and rinsed with
deionized H2O.
Scaffold Preparation
Triplicate scaffolds were prepared in polytetrafluoroethyl-
ene molds producing cylindrical scaffolds 12 mm in length and
6 mm in diameter. PLGA/PEG particles were mixed with saline
and varying alginate bead masses to give a range of weight per-
centages from 0% to 80% alginate. Ratio of PLGA/PEG particles
to saline was 1:0.6 (particles:saline). Particle paste was packed
into the mold, which was placed at 37C for 4 hours to allow
scaffold formation. For cell seeding experiments, scaffolds were
UV sterilized for 80 minutes.
Ciprofloxacin-loaded scaffolds were prepared for drug-
release assays using two different methods, A and B. In method
A, ciprofloxacin solution (Sigma-Aldrich) was mixed with the
PLGA/PEG particles and alginate beads to produce a paste,
which was used to prepare scaffolds as described previously
(100 lg ciprofloxacin per scaffold). In method B, ciprofloxacin
was added into the PLGA/PEG melt-blend at 80C to 90C on a
hotplate. The ciprofloxacin-PLGA/PEG particles were then
fabricated and used to produce scaffolds as described (100 lg
ciprofloxacin per scaffold).
Porosity Measurements
Triplicate scaffolds prepared using 100% PLGA/PEG, 80%
PLGA/PEG-20% alginate, 60% PLGA/PEG-40% alginate, 40%
PLGA/PEG-60% alginate and 20% PLGA/PEG-80% alginate
were sintered for 4 hours at 37C followed by freeze-drying for
24 hours, causing the alginate beads to dehydrate. The porosity
of the scaffolds was calculated using the bulk density (BD) and
particle density (PD) values as follows: (12BD)/(PD 3 100)5%
Porosity.
X-ray Micro-Computed Tomography
High-resolution three-dimensional (3D) images of the
mastoid bone and scaffold samples were acquired using a labo-
ratory x-ray micro-computed tomography (CT) system (lCT-40;
Scanco Medical AG, Br€uttisellen, Switzerland). The recon-
structed field of view was 12.3 mm for the scaffold specimens
and 30.7 mm for the mastoid bone specimen, with isotropic
nominal resolutions of 12 and 15 lm, respectively. Approxi-
mately 1 cm in length was scanned, spanning 800 slices
(scaffolds) or 667 slices (bone). The bone or scaffold structure
was binarized using a visually selected fixed global threshold.
The surface of the 3D structure was triangulated and
displayed using the manufacturer’s software (lCT Ray v3.8;
Scanco Medical AG).
Mechanical Properties
PLGA/PEG particles sinter over time at 37C to form scaf-
folds. Assessing the mechanical properties of the scaffolds over
time at 37C reveals if solidification due to particle sintering
has occurred. Triplicate scaffolds prepared using 40% PLGA/
PEG-60% alginate were sintered at 37C for 3, 4, or 5 hours.
Compressive strength was tested using a TA.HDPlus texture
analyzer (Stable Microsystems, Surrey, UK).
Scanning Electron Microscopy
Scaffolds were mounted on aluminum stubs and sputter-
coated with gold at an argon current rate of 30 mA for 3
minutes. Scaffold structural morphology was examined using a
scanning electron microscope (Jeol, Herts, UK; model JSM-
6060LV) at 10 kV.
Human Bone Marrow Mesenchymal Stem Cell
Culture
Human bone marrow mesenchymal stem cells (hBM-
MSCs) were cultured in mesenchymal stem cell media (TCS
Cell Works, Buckingham, UK) supplemented with 5% fetal calf
serum, 1% mesenchymal stem cell growth supplement, 1% peni-
cillin/streptomycin solution (all TCS Cell Works), 1% L-gluta-
mine (Gibco, Paisley, UK) (200 mM), and 1% nonessential
amino acids (Sigma-Aldrich). Cells were maintained in a
humidified tissue-culture incubator at 37C and with 5% CO2.
Cell Seeding on Scaffolds
Triplicate scaffolds for both test and control groups were
pre-wet with 100 lL media and placed in the incubator at 37C
for 1 hour. Then 2 3 105 cells in a 30 lL suspension was seeded
per scaffold. The scaffolds were incubated for 2 hours at 37C
before the addition of 1 mL media to each well.
Prestoblue Metabolic Activity Assay
The Prestoblue (Invitrogen Life Sciences, Paisley, UK)
metabolic activity assay was performed on triplicate scaffolds 1,
2, 3, 5, and 7 days postseeding. Each scaffold was submerged in
1 mL of media. A total of 111 lL of Prestoblue was added to
each well, and the scaffolds were incubated at 37C for 25
minutes. Triplicate 100 lL media samples from each well were
read on a Tecan plate reader with the excitation wavelength set
to 535 nm and the emission wavelength set at 615 nm.
Live/Dead Staining
Live/dead staining was performed on triplicate scaffolds 3
days postseeding. A staining solution was prepared in PBS
containing 20 lg mL21 propidium iodide (Sigma-Aldrich) and 1
lg mL21 fluorescein diacetate (Calbiochem, Watford, UK). Then
1 mL of the staining solution was added to each scaffold and
incubated at room temperature for 15 minutes before visualiza-
tion using a Leica LCS confocal macroscope. Live cells stain
green and dead cells stain red.
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Ciprofloxacin Release Assay
Triplicate scaffolds loaded with 100 lg ciprofloxacin
prepared using method A or B as described previously were
placed in 3 mL PBS and incubated at 37C. At various time
intervals, the PBS was replaced with 3 mL fresh PBS, and
100 lL of PBS containing released drug was sampled in tripli-
cate at 315 nm on a plate reader (Tecan, Reading, UK) and
concentration of drug measured. Non–drug loaded scaffolds
containing only PBS were used as a control for background
absorbance values. Data are presented as cumulative drug
release as a function of time.
RESULTS
Microstructure of Human Mastoid Bone
Human mastoid bone microstructure was analyzed
using micro-CT. The porosity of the bone was 83%. The
Fig. 1. Microstructure of human mastoid bone. (A) Micro-computed tomography (CT) x-ray slice image of human mastoid bone. (B) Micro-
CT three-dimensional reconstruction of human mastoid bone. [Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
Fig. 2. Microstructure of poly(DL-lactic acid-co-glycolic acid) (PLGA)/poly(ethylene glycol) (PEG)-alginate scaffolds. (A) Porosity of PLGA/
PEG-alginate scaffolds calculated by density measurements. (B) Light microscope images of 40% PLGA/PEG-60% alginate scaffolds
before freeze-drying (top image) and after freeze-drying for 24 hours (bottom image). (C) Micro-computed tomography x-ray slice and
three-dimensional reconstruction of 40% PLGA/PEG-60% alginate scaffold after freeze-drying for 24 hours [Color figure can be viewed in
the online issue, which is available at wileyonlinelibrary.com.].
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physiology of the bone was observed in both x-ray
images and 3D reconstruction (Fig. 1). Pores were
observed throughout the structure with sizes averaging
1.3 mm, as measured by micro-CT.
Microstructure of PLGA/PEG-Alginate
Composite Scaffolds
Scaffolds containing different amounts of alginate
beads were sintered for 4 hours. At 37C, alginate
degrades in 3 to 4 days, whereas PLGA/PEG particles
degrade in 2 to 3 months. Therefore the alginate beads
will degrade rapidly in vivo, leaving a highly porous
PLGA/PEG scaffold structure. To mimic this degradation
effect, the scaffolds were freeze-dried for 24 hours before
porosity measurements to dehydrate the alginate beads.
Porosity was assessed by density measurements and
increased from 43% (100% PLGA/PEG-0% alginate) to
78% (20% PLGA/PEG-80% alginate) (Fig. 2A). The 20%
PLGA/PEG-80% alginate scaffolds were fragile when
handled during cell culture experiments, therefore 40%
PLGA/PEG-60% alginate scaffolds were used in all sub-
sequent experiments (herein referred to as PLGA/PEG-
alginate scaffolds).
Light microscope images of PLGA/PEG-alginate
scaffolds were taken before and after freeze-drying (Fig.
2B). The residual pores created by the dehydrated algi-
nate beads can be seen in the image after freeze-drying
and in the micro-CT images in Figure 2C. PLGA/PEG-
alginate scaffolds were submerged in saline for 2 weeks
at 37C to visually compare the physical structure of
mastoid bone with the scaffolds following alginate bead
degradation at this temperature (Fig. 3).
Particle Sintering Within PLGA/PEG-Alginate
Scaffolds
PLGA/PEG-alginate scaffolds were sintered for 3, 4,
and 5 hours at 37C. Compressive strength tests were
performed to assess the ability of the PLGA/PEG par-
ticles to sinter in the presence of alginate beads (Fig. 4).
Following 3 hours at 37C, the compressive strength val-
ues were 20 kPa on average. This increased over the
next hour at 37C to 0.2 MPa and further increased to
0.38 MPa by 5 hours. The microstructure of a scaffold
sintered for 4 hours at 37C and freeze-dried for 24
hours is shown in the scanning electron microscopy
image in Figure 4B.
Cell Proliferation on PLGA/PEG-Alginate
Scaffolds
The hBM-MSCs were seeded onto the scaffolds, and
the Prestoblue cell viability assay was performed over 7
Fig. 3. Image comparison of human mastoid bone and poly(DL-
lactic acid-co-glycolic acid) (PLGA)/poly(ethylene glycol) (PEG)
scaffold. Light microscope image of human mastoid bone section
(left) and 40% PLGA/PEG-60% alginate scaffold (right). Scaffold
was submerged in saline at 37C for 2 weeks before imaging.
Fig. 4. Poly(DL-lactic acid-co-glycolic acid) (PLGA)/poly(ethylene
glycol) (PEG) particle sintering within PLGA/PEG-alginate scaffolds
at 37C. (A) Compressive strength of 40% PLGA/PEG-60% algi-
nate scaffolds sintered for 3, 4, and 5 hours at 37C. Error bars
represent standard deviation. (B) Representative scanning electron
microscopy image of a 40% PLGA/PEG-60% alginate scaffold
sintered for 4 hours at 37C and freeze-dried for 24 hours.
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days (Fig. 5A). The cell number increased during this
time from 2 3 105 cells per scaffold to 6.8 3 105 cells per
scaffold, demonstrating hBM-MSC proliferation. Scaf-
folds were subjected to live/dead staining 3 days after
cell seeding to visualize viable (green) and nonviable
(red) hBM-MSCs within the scaffolds (Fig. 5B).
Antibiotic Release From PLGA/PEG-Alginate
Scaffolds
Ciprofloxacin-loaded scaffolds were prepared as
described previously using two different loading methods
for scaffold preparation, A and B. In method A, ciproflox-
acin solution was mixed with the PLGA/PEG particles
and alginate beads to produce a paste, which was used
to prepare scaffolds as described (100 lg ciprofloxacin
per scaffold). In method B, the appropriate amount of
ciprofloxacin was added into the PLGA/PEG melt-blend.
High burst release of ciprofloxacin after 24 hours (73%)
was observed with the scaffolds prepared using method
A (Fig. 6). Burst release was minimized to 30% using
method B, where the drug was mixed within the PLGA/
PEG at the melt-blend phase. Ciprofloxacin release from
scaffolds prepared using method A slowed down to an
average of 0.1% drug release per day from day 7 until
day 53 when release stopped at a total of 97% ciprofloxa-
cin released.
DISCUSSION
An ideal material for mastoid air-cell regeneration has
not yet been identified, therefore alternatives have been
investigated in recent years including biphasic calcium
phosphate granules mixed with fibrin sealant and polycap-
rolactone-tricalcium phosphate composites.7,8 These materi-
als contain ceramic components that may have similar
disadvantages to hydroxyapatite for this application, such
as extrusion and infection. Bioactive glasses such as BonA-
live (BonAlive Biomaterials, Turku, Finland) have recently
been reported to show promise in mastoid bone repair proce-
dures; however, the glass granules occasionally leak into the
ear canal.9 Biodegradable materials have also been assessed
including cell-loaded hyaluronic acid gel and growth factor-
loaded collagen implants.10,11 These materials show promise
for bone repair, but they lack the macroporosity required to
regenerate the highly porous structure of the mastoid air-
cell system.
Here we describe the development of a biodegrad-
able polymer scaffold tailored for mastoid air-cell regen-
eration. The scaffold is based on PLGA/PEG particle
paste, which can be molded into any size or shape and
hardens into a solid scaffold at 37C.5 To our knowledge,
this is the first description of a biodegradable particulate
polymer scaffold that can be pasted into a cavity and
that hardens in vivo for this application. The ability to
paste the scaffold around the mastoid cavity offers
improved clinical application and tissue approximation
when compared to implants.
To aid scaffold design it is important to take into
account the structure of the mastoid air cells. Therefore
mastoid bone was visualized using light microscopy and
Fig. 5. Proliferation of human bone marrow-derived mesenchymal
stem cells on poly(DL-lactic acid-co-glycolic acid) (PLGA)/poly
(ethylene glycol) (PEG)-alginate scaffolds. (A) Number of viable
human bone marrow mesenchymal stem cells (hBM-MSCs) on
40% PLGA/PEG-60% alginate as measured by the Prestoblue
metabolic activity assay over 7 days in culture. Error bars repre-
sent standard deviation. (B) Representative images of hBM-MSC-
seeded 40% PLGA/PEG-60% alginate scaffold 3 days postseed-
ing following live/dead staining. PLGA/PEG particles rendered in
blue using Leica LCS confocal macroscope software to visualize
the particles (blue) and pore spaces between particles (black).
Size bar5200 lm. [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
Fig. 6. Ciprofloxacin release from poly(DL-lactic acid-co-glycolic
acid) (PLGA)/poly(ethylene glycol) (PEG)-alginate scaffolds. Cumu-
lative release profiles for ciprofloxacin from 40% PLGA/PEG-60%
alginate scaffolds represented as percentage of total loaded drug
released. Two different drug-loading methods were used, method
A (PLGA/PEG-alginate cipro) and method B (PLGA/PEG-alginate
cipro melt-blend).
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micro-CT. The overall porosity of the bone was measured
at 83% with an average pore diameter of 1.3 mm. Our
intention was to optimize scaffold structure with regard
to generating large air cells mimicking those observed in
mastoid bone. Alginate beads of 1- to 1.5-mm diameter
were successfully used as porogens to create pores in the
PLGA/PEG scaffolds. Scaffold porosity was enhanced
from 43% to 78% with increasing amount of alginate
beads.
In the current study, the mastoid bone sample dis-
played a porosity level of 83%. The scaffold formulation
with a porosity value closest to that of the mastoid bone
sample was 20% PLGA/PEG-80% alginate, at 78%.
Because of the fact that scaffolds produced using this
formulation were fragile when handled during cell cul-
ture experiments, 40% PLGA/PEG-60% alginate scaf-
folds (64% porous) were used in all subsequent
experiments. It will be important to assess the ability of
both formulations to regenerate mastoid air cells in
future in vivo studies to determine the best formulation
to take forward for clinical use.
The ability of the scaffold to harden at body temper-
ature is an important property, as it ensures the polymer
is retained where it is applied. This hardening process
could potentially allow the polymer to act as an oblitera-
tion material in addition to promoting air-cell regenera-
tion within the mastoid bone. As the formulation
contained 60% alginate beads, it was necessary to assess
the ability of the PLGA/PEG particles to sinter in this
formulation. Scaffold hardening at 37C was demon-
strated by an increase in scaffold compressive strength
over time, confirming the ability of the PLGA/PEG par-
ticles to fuse into a solid scaffold in the presence of the
alginate beads.
PLGA/PEG scaffolds are capable of regenerating
bone in vivo. The formulation used in the current study
contained 40% PLGA/PEG and 60% alginate; therefore
the ability of hBM-MSCs to grow on the scaffolds in
vitro was assessed. Our results demonstrate attachment
and proliferation of hBM-MSCs on the scaffolds over a
7-day period, demonstrating the potential for cells to
proliferate on the scaffolds, which has implications for
their successful use for bone repair in vivo.
To reduce the likelihood of secondary complications
arising from postoperative infection or recurrence of
underlying middle ear infections, we incorporated cipro-
floxacin into the PLGA/PEG-alginate scaffold formula-
tion as it is commonly used in the treatment of middle
ear infections. We used two different antibiotic loading
methods. Method A involved mixing the drug into the
PLGA/PEG and alginate bead paste before scaffold for-
mation, trapping the drug inside the scaffold during sol-
idification at 37C. Method B involved mixing the drug
into the PLGA/PEG at the melt-blend phase, therefore
loading it inside the particles. Incorporation of ciproflox-
acin into polymer melt-blends at high temperature
(80C–150C) has been reported using polycaprolactone/
poloxamine, with the antibiotic being shown to retain its
antibacterial activity following exposure to these high
temperatures.12 In our method, the ciprofloxacin was
heated to 80C. A high burst release of 73% ciprofloxacin
after 24 hours was observed with the scaffolds prepared
using method A, caused by drug on the surface of the
particles releasing immediately. This burst release was
minimized to 30% using method B, as the drug is
trapped inside the particles, therefore reducing the
amount of drug available for immediate release. Scaf-
folds produced using method A released for 7 weeks,
with a daily release rate of approximately 0.1% per day.
Scaffolds produced using method B generated an
improved release profile with a lower burst release
phase followed by 10 weeks release of approximately 1%
per day.
CONCLUSION
We describe the development of a porous, biode-
gradable PLGA/PEG-alginate scaffold that can be pasted
into a cavity of any size or shape. Scaffold porosity can
be controlled by varying the amount of alginate beads in
the formulation, with a maximum of porosity of 78%
achieved. The scaffolds support the growth of hBM-
MSCs and display sustained release of ciprofloxacin for
7 to 10 weeks in vitro. Future studies will focus on the
assessment of this scaffold formulation for mastoid air-
cell regeneration in vivo.
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